Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy

Gastroenterology Nursing

Volumn 33, Issue 5, 2010, Pages 368-373

  Rodis, Jennifer L ^a   Kibbe, Pamella ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; HEPATITIS C; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HEPATITIS C; HUMANS; MALE; MEDICATION ADHERENCE; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 77958579821     PISSN: 1042895X     EISSN: 15389766     Source Type: Journal    
DOI: 10.1097/SGA.0b013e3181f443cb     Document Type: Article

References (27)

1. Akincigil, A., Bowblis, J. R., Levin, C., Walkup, J. T., Jan, S., & Crystal, S. (2007). Adherence to antidepressant treatment among privately insured patients diagnosed with depression. Medical Care, 45(4), 363-369.
2. Bernstein, D., Kleinman, L., Barker, C. M., Revicki, D. A., & Green, J. (2002). Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology, 35(3), 704-708.
3. Braitstein, P., Montessori, V., Chan, K., Montaner, J. S., Schechter, M. T., OShaughnessy, M. V., et al. (2005). Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: Outcomes from a population-based cohort. AIDS Care, 17(4), 505-515.
4. Chang, S. C., Ko, W. S., Wu, S. S., Peng, C. Y., & Yang, S. S. (2008). Factors associated with quality of life in chronic hepatitis C patients who received interferon plus ribavirin therapy. Journal of the Formosan Medical Association- Taiwan Yi Zhi, 107(6), 454-462.
5. Darling, J. M., & Fried, M. W. (2006). Optimizing treatment regimens in hepatitis C. Clinics in Liver Disease, 10(4), 835-850.
6. Dienstag, J., & McHutchison, J. G. (2006). American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology, 130(1), 231-264.
7. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Jr., et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine, 347(13), 975-982.
8. Hassanein, T., Cooksley, G., Sulkowski, M., Smith, C., Marinos, G., Lai, M. Y., et al. (2004). The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. Journal of Hepatology, 40(4), 675-681.
9. Helbling, B., Overbeck, K., Gonvers, J. J., Malinverni, R., Dufour, J. F., Borovicka, J., et al. (2008). Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. Gut, 57(11), 1597-1603.
10. Kolor, B. (2005). Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic. Pharmacotherapy, 25(9), 1230-1241.
11. Kontorinis, N., Garas, G., Young, J., Speers, D., Chester, B. P., MacQuillan, G. C., et al. (2003). Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic. Internal Medicine Journal, 33, 500-504.
12. Leone, N. E. (2002). The role of nursing in managing treatmentassociated adverse effects in patients with hepatitis C. Gastroenterology, 25(5), 201-203.
13. Lo Re, V., III, Amorosa, V. K., Localio, A. R., OFlynn, R., Teal, V., Dorey-Stein, Z., & Gross, R. (2009). Adherence to hepatitis C virus therapy and early virologic outcomes. Clinical Infectious, 48(2), 186-193.
14. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., et al. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet, 358(9286), 958-965.
15. Martin-Santos, R., Diez-Quevedo, C., Castellvi, P., Navines, R., Miquel, M., Masnou, H., et al. (2008). De novo depression and anxiety disorders and influence on adherence during peginterferonalpha- 2a and ribavirin treatment in patients with hepatitis C. Alimentary Pharmacology & Therapeutics, 27(3), 257-265.
16. Morisky, D. E., Green, L. W., & Levine, D. M. (1986). Concurrent and predictive value of a self-reported measure of medication adherence. Medical Care, 24(1), 67-74.
17. QualityMetric Incorporated, Medical Outcomes Trust. (2002). SF12v12 health survey. Retrieved July 10, 2006, from
18. Raptopoulou, M., Tsantoulas, D., Vafiadi, I., Ketikoglou, I., Paraskevas, E., Vassiliadis, T., et al. (2005). The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients. Journal of Viral Hepatitis, 12(1), 91-95.
19. Rodger, A. J., Jolley, D., Thompson, S. C., Lanigan, A., & Crofts, N. (1999). The impact of diagnosis of hepatitis C virus on quality of life. Hepatology, 30(5), 1299-1301.
20. Saunders, J. C., & Cookman, C. A. (2005). A clarified conceptual meaning of hepatitis C-related depression. Gastroenterology Nursing, 28(2), 123-129; quiz 130-131.
21. Shah, B., Walshe, L., Saple, D. G., Mehta, S. H., Ramnani, J. P., Kharkar, R. D., et al. (2007). Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. Clinical Infectious, 44(9), 1235-1244.
22. Smith, J. P. (2008). Treatment options for patients with hepatitis C: Role of pharmacists in optimizing treatment response and managing adverse events. Pharmacotherapy, 28(9), 1151-1161.
23. Spiegel, B. M., Younossi, Z. M., Hays, R. D., Revicki, D., Robbins, S., & Kanwal, F. (2005). Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology, 41(4), 790-800.
24. Svarsted, B. L., Chewning, B. A., Sleath, B. L., & Claesson, C. (1999). The Brief Medication Questionnaire: A tool for screening patient adherence and barriers to adherence. Patient Education & Counseling, 37, 113-124.
25. Taliani, G., Rucci, P., Biliotti, E., Cirrincione, L., Aghemo, A., Alberti, A., et al. (2007). Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection. Journal of Viral Hepatitis, 14(12), 875-882.
26. Von Wagner, M., & Lee, J. H. (2006). Impaired health-related quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels. Journal of Viral Hepatitis, 13(12), 828-834.
27. Younossi, Z., Kallman, J., & Kincaid, J. (2007). The effects of HCV infection and management on health-related quality of life. Hepatology, 45(3), 806-816.